Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
